---
title: "Helix BioPharma closes C$3,673,000 convertible debenture placement"
url: "https://aibio.space/news/helix-biopharma-closes-c-3-673-000-convertible-debenture-placement/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-06-03"
section: "Debt Financing"
tickers: "TSX:HBP"
source: "https://www.helixbiopharma.com/fy2026/helix-biopharma-corp-announces-closing-of-private-placement-of-convertible-debentures/"
summary: "The unsecured debentures carry 25.00% simple interest, mature 14 months after closing and can convert at C$1.42 per share."
---

By the aibio.space news desk.

Sources

- [Helix BioPharma Corp. release (2026-06-03)](https://www.helixbiopharma.com/fy2026/helix-biopharma-corp-announces-closing-of-private-placement-of-convertible-debentures/)

[HBP](https://aibio.space/companies/helix-biopharma/)

2026-06-03

# Helix BioPharma closes C$3,673,000 convertible debenture placement

Tickers [HBP](https://aibio.space/companies/helix-biopharma/)

The unsecured debentures carry 25.00% simple interest, mature 14 months after closing and can convert at C$1.42 per share.

## Key facts

- **Company**: Helix BioPharma Corp. (TSX: HBP)

- **News type**: Debt Financing

- **Primary source**: [Helix BioPharma Corp. release (2026-06-03)](https://www.helixbiopharma.com/fy2026/helix-biopharma-corp-announces-closing-of-private-placement-of-convertible-debentures/)

*An empty boardroom with a long table. CC0, via rawpixel. The picture shows the field, not the companies named.*

Helix BioPharma Corp. closed a non-brokered private placement of unsecured convertible debentures, announced on June 3, 2026. The company issued 3,673 convertible debentures for aggregate gross proceeds of C$3,673,000.

The principal and any unpaid accrued interest are due 14 months from the closing date. Each debenture bears interest at 25.00% per annum, calculated on a simple interest basis.

If the debentures are not repaid by the maturity date, the outstanding principal may be converted by the holder into common shares at C$1.42 per share. That price is the market price as of the price reservation date, less the permitted 20% discount under TSX policies.

Any accrued but unpaid interest may also convert on the maturity date. The interest conversion price is the greater of the conversion price and the volume weighted average trading price of the shares on the TSX over the five trading days before the relevant date, less the TSX permitted discount.

The release describes the offering as non-brokered and names no placement agent or advisor.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

HBP

Helix BioPharma Corp.

TSX · Canada

Open the starter desk

## More in Debt Financing

Debt Financing

### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/)

Oct 30, 2026

Debt Financing

### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/)

Oct 30, 2026

Debt Financing

### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/)

Oct 29, 2026

---
Source page: https://aibio.space/news/helix-biopharma-closes-c-3-673-000-convertible-debenture-placement/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Helix BioPharma closes C$3,673,000 convertible debenture placement", 2026-06-03, https://aibio.space/news/helix-biopharma-closes-c-3-673-000-convertible-debenture-placement/